KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short term Debt (2019 - 2025)

Castle Biosciences (CSTL) has disclosed Short term Debt for 5 consecutive years, with $417000.0 as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 50.0% to $417000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $417000.0 through Dec 2025, up 50.0% year-over-year, with the annual reading at $417000.0 for FY2025, 50.0% up from the prior year.
  • Short term Debt hit $417000.0 in Q4 2025 for Castle Biosciences, down from $1.9 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $20.8 million in Q1 2022 to a low of $278000.0 in Q4 2024.
  • Historically, Short term Debt has averaged $4.9 million across 3 years, with a median of $1.1 million in 2025.
  • Biggest YoY gain for Short term Debt was 50.0% in 2025; the steepest drop was 50.0% in 2025.
  • Year by year, Short term Debt stood at $20.8 million in 2022, then tumbled by 98.67% to $278000.0 in 2024, then skyrocketed by 50.0% to $417000.0 in 2025.
  • Business Quant data shows Short term Debt for CSTL at $417000.0 in Q4 2025, $1.9 million in Q2 2025, and $1.1 million in Q1 2025.